• Andri Andreou, Sofia Trantza, Demetrios Filippou, Nikolaos Sipsas, and Sotirios Tsiodras.
• Pharmaceutical Services, Ministry of Health of the Republic of Cyprus, Nicosia, Cyprus sophia.trantza@gmail.com antri_antreou@yahoo.com.
• In Vivo. 2020 Jun 1; 34 (3 Suppl): 1567-1588.

BackgroundOn March 11, 2020, the World Health Organization (WHO) declared the outbreak of coronavirus disease (COVID-19) a pandemic. Since then, thousands of people have suffered and died, making the need for a treatment of severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) more crucial than ever.Materials And MethodsThe authors carried out a search in PubMed, ClinicalTrials.gov and New England Journal of Medicine (NEJM) for COVID-19 to provide information on the most promising treatments against SARS-CoV-2.ResultsPossible COVID-19 agents with promising efficacy and favorable safety profile were identified. The results support the combination of copper, N-acetylcysteine (NAC), colchicine and nitric oxide (NO) with candidate antiviral agents, remdesivir or EIDD-2801, as a treatment for patients positive for SARS-CoV-2.ConclusionThe authors propose to study the effects of the combination of copper, NAC, colchicine, NO and currently used experimental antiviral agents, remdesivir or EIDD-2801, as a potential treatment scheme for SARS-COV-2.Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

70 keywords...

hide…